Fresenius Kabi Makes Progress On Tocilizumab

Reports Positive Phase I Results For Actemra/Ro-Actemra Biosimilar

 
• By Dave Wallace

Fresenius Kabi has reported positive Phase I data for its MSB11456 proposed tocilizumab biosimilar rival to Actemra/Ro-Actemra, against the backdrop of shortages for the brand which is being used in some regions to treat COVID-19.

Tocilizumab injection Syringe
Fresenius Kabi’s MSB11456 tocilizumab candidate is moving ahead • Source: Alamy

More from Biosimilars

More from Products